Switch from Intravenous to Subcutaneous Immunoglobulin in CIDP and MMN: 12 Months Results from an Observational Study.

ABSTRACT:

Introduction

Since 2018 subcutaneous immunoglobulin (SCIg) has been approved for the maintenance treatment of chronic inflammatory demyelinating polyneuropathy (CIDP). However, comprehensive real-world data for long-term SCIg treatment are scarce for CIDP and especially for other immune-mediated neuropathies such as multifocal motor neuropathy (MMN).

Methods

In this observational study, 62 patients with CIDP and 13 with MMN were analyzed. Patients had been receiving regular intravenous immunoglobulin (IVIg) and transitioned to an equivalent weekly dose of SCIg. A comprehensive set of biographical, clinical, and paraclinical data were compared between the time of the switch and after 12 months.

Results

Subcutaneous administration was continued by 84% of the patients wi

SUBMITTER: Gingele S 

PROVIDER: S-EPMC12804488 | biostudies-literature | 2026 Feb

REPOSITORIES: biostudies-literature